Krystal Biotech, Inc.

Krystal Biotech, Inc.

59.94
BRL
+3.24
(+5.71%)
1.32EPS
Mar 01Next Earn

Important Dates

Krystal Biotech Inc Unsponsored BDR's next confirmed earnings release is scheduled for March 1, 2027.

Earnings Date3/1/2027

Share Statistics

As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR has 854.27M shares outstanding.

Shares Outstanding854.27M

Financial Position

As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR maintains a current ratio of 7.89, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.

Current Ratio7.89
Quick Ratio7.35
Debt / Equity0.60
Debt / EBITDA0.04

Financial Efficiency

BRL

Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR posted a return on equity (ROE) of 17.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.38, useful for judging operating efficiency across full business cycles. The company generates approximately 8.26M in revenue per employee across its workforce of 295.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.61 indicates how many times Krystal Biotech Inc Unsponsored BDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)17.50
Return on Assets (ROA)15.93
Return on Invested Capital (ROIC)15.12
Return on Capital Employed (ROCE)17.38
Revenue Per Employee8.26M
Employee Count295.00
Inventory Turnover0.61

Taxes

BRL

Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR recorded 174.28M in income tax expense. That works out to an effective tax rate of 12.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.34B, leaving 1.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax174.28M
Effective Tax Rate12.99

Income Statement

BRL

Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR generated 2.44B in revenue and converted that into 1.17B in net income, yielding earnings per share of 1.32. EBITDA reached 1.21B, while operating income came in at 1.18B.

Revenue2.44B
Gross Profit2.30B
Operating Income1.18B
Pretax Income1.34B
Net Income1.17B
EBITDA1.21B
EBIT1.18B
Earnings Per Share (EPS)1.32

Balance Sheet

BRL

As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR holds 4.73B in cash and equivalents against 44.51M in total debt, resulting in a net debt position of -2.40B. Total book value stands at 7.44B, with working capital of 5.08B providing operational flexibility.

Cash & Cash Equivalents4.73B
Total Debt44.51M
Net Debt-2.40B
Equity (Book Value)7.44B
Book Value Per Share8.71
Working Capital5.08B

Cash Flow

BRL

Krystal Biotech Inc Unsponsored BDR produced 1.68B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -71.77M in capital expenditures, free cash flow totaled 1.61B - equivalent to 1.90 per share.

Operating Cash Flow1.68B
Capital Expenditures-71.77M
Free Cash Flow1.61B
FCF Per Share1.90

Margins

Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR posted a gross margin of 94.28, reflecting its pricing power and cost economics. The operating margin of 48.41 and net profit margin of 47.91 provide insight into operational efficiency.

Gross Margin94.28
Operating Margin48.41
Pretax Margin55.06
Profit Margin47.91
EBITDA Margin49.84